VENTURE CAPITAL POST

Valeant Pharmaceuticals, Inc. of Canada has partnered with AstraZeneca for the selling rights of psoriasis drug brodalumab. Amgen Inc. ended its partnership with AstraZeneca due to its worries over the drug's side effects.

Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs.

Pfizer Inc (PFE.N) reported stronger-than-expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets, but did not signal any acquisition plans following its recent failed efforts to buy rival British drugmaker AstraZeneca Plc (AZN.L).

Amgen Inc (AMGN.O), one of the world's largest biotechnology companies, will unveil next week its first strategy update since early 2013, but few expect a major shift like the split-up recently proposed by Daniel Loeb's Third Point hedge fund.

The buyout of Onyx Pharmaceuticals was tainted with conflicts of interest and undervaluation, according to its shareholders.

As Amgen Inc's acquisition of Onyx Pharmeceuticals Inc comes to a close, Amgen Chief Executive Officer Robert Bradway is lauded for being a great dealmaker.

Amgen was looking into buying more small-sized but profitable firms after its successful bid with Onyx Pharmaceuticals.

Amgen Inc. might announced the agreement to acquire Onyx Pharmaceuticals Inc. for USD 125 per share piece as soon as Monday.